- RougeTx launches with $58 million series A financing for HHT therapy
- Lundbeck presents phase 1b data for Lu AF28996 in advanced Parkinson’s disease
- Bespak and SNBL agree global access deal for FDA‑approved nasal device
- NEMLUVIO data show sustained three‑year responses in atopic dermatitis
- SMC accepts AQUIPTA for eligible migraine patients in Scotland
- MINT study results strengthen real‑world evidence for mogamulizumab
- SMC accepts vutrisiran for eligible patients in Scotland
- NHS Blood and Transplant partners with Northwest Biotherapeutics
- Laverock unveils new in vivo programmes in oncology
- Atrogi reports human data showing muscle gains with ATR‑258
- Group B Strep mums urge women to join vaccine trial
- NICE backs Tryngolza for FCS treatment
- Survodutide delivers weight loss and glycemic gains in phase 3 trial
- Survodutide delivers weight loss and glycemic gains in phase 2 trial
- Quotient and Acesion partner on ai‑enhanced formulation
- Kither begins dosing in COPD trial of KIT2014
- Teva secures FDA approval for Degevma biosimilar
- Novotech to acquire Agilex Biolabs
- Nezglyal approved in EU for childhood cALD
- NICE backs first systemic therapy for desmoid tumours
Website: https://www.pharmatimes.com
